Pinometostat
CAS No. : 1380288-87-8
(Synonyms: EPZ-5676)
| Size | Price | Stock |
|---|---|---|
| 5mg | $70 | In-stock |
| 10mg | $100 | In-stock |
| 25mg | $210 | In-stock |
| 50mg | $360 | In-stock |
| 100mg | $600 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-15593 |
| M.Wt: | 562.71 |
| Formula: | C30H42N8O3 |
| Purity: | >98 % |
| Solubility: | Ethanol : 100 mg/mL (ultrasonic);DMSO : 100 mg/mL (ultrasonic) |
Pinometostat (EPZ-5676) is a potent DOT1L histone methyltransferase inhibitor with a Ki of 80 pM. IC50 & Target: Ki: < 80 pM (DOT1L histone methyltransferase) In Vitro: Pinometostat (EPZ-5676) inhibits H3K79me2 with IC50 values of 3 nM and 5 nM in MV4-11 and HL60 cells, respectively. Pinometostat (EPZ-5676) is a potent inhibitor of MV4-11 proliferation with an IC50 value of 3.5 nM[1]. Pinometostat (EPZ-5676) induces a synergistic and durable antiproliferative effect, increases expression of differentiation markers and apoptosis as single agent, and demonstrates combination benefit in combination with AML standard of care drugs in MLL-r cells[2]. In Vivo: Pinometostat (EPZ-5676) (70 mg/kg, i.p.) causes complete and sustained regression in a rat xenograft model of MLL-rearranged leukemia. Pinometostat (EPZ-5676) (70, 35 mg/kg, i.v.) reduces HOXA9 and MEIS1 mRNA levels of tumors taken from rats, and reduces MLL-fusion target gene expression in vivo[1].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- Pinometostat
- Cat. No.:
- HY-15593
- Quantity:
Your information is safe with us.